RESUMEN
The emergence of compulsive drug-seeking habits, a hallmark feature of substance use disorder, has been shown to be predicated on the engagement of dorsolateral striatal control over behaviour. This process involves the dopamine-dependent functional coupling of the anterior dorsolateral striatum (aDLS) with the nucleus accumbens core, but the mechanisms by which this coupling occurs have not been fully elucidated. The striatum is tiled by a syncytium of astrocytes that express the dopamine transporter (DAT), the level of which is altered in individuals with heroin use disorder. Astrocytes are therefore uniquely placed functionally to bridge dopamine-dependent mechanisms across the striatum. Here we tested the hypothesis that exposure to heroin influences the expression of DAT in striatal astrocytes across the striatum before the development of DLS-dependent incentive heroin seeking habits. Using Western-blot, qPCR, and RNAscope™, we measured DAT protein and mRNA levels in whole tissue, culture and in situ astrocytes from striatal territories of rats with a well-established cue-controlled heroin seeking habit and rats trained to respond for heroin or food under continuous reinforcement. Incentive heroin seeking habits were associated with a reduction in DAT protein levels in the anterior aDLS that was preceded by a heroin-induced reduction in DAT mRNA and protein in astrocytes across the striatum. Striatal astrocytes were also shown to be susceptible to direct dopamine- and opioid-induced downregulation of DAT expression. These results suggest that astrocytes may critically regulate the striatal dopaminergic adaptations that lead to the development of incentive heroin seeking habits.
Asunto(s)
Astrocitos , Cuerpo Estriado , Proteínas de Transporte de Dopamina a través de la Membrana Plasmática , Dopamina , Comportamiento de Búsqueda de Drogas , Heroína , Animales , Proteínas de Transporte de Dopamina a través de la Membrana Plasmática/metabolismo , Astrocitos/metabolismo , Astrocitos/efectos de los fármacos , Cuerpo Estriado/metabolismo , Cuerpo Estriado/efectos de los fármacos , Masculino , Ratas , Comportamiento de Búsqueda de Drogas/fisiología , Comportamiento de Búsqueda de Drogas/efectos de los fármacos , Heroína/farmacología , Heroína/administración & dosificación , Dopamina/metabolismo , Motivación/efectos de los fármacos , Motivación/fisiología , Dependencia de Heroína/metabolismo , Ratas Sprague-DawleyRESUMEN
Drug dependence is a chronic brain disease characterized by craving and recurrent episodes of relapse. Tramadol HCl is a promising agent for withdrawal symptoms management, considering its relatively low abuse potential and safety. Oral administration, however, is not preferred in abstinence maintenance programs. Introducing an implantable, long-lasting formula is suggested to help outpatient abstinence programs achieve higher rates of treatment continuation. Tramadol implants (T350 and T650) were prepared on polycaprolactone polymer ribbons by the wet method. Male Wistar rats were adapted to heroin-conditioned place preference (CPP) at escalating doses (3-30 mg/kg, intraperitoneally, for 14 days). Implants were surgically implanted in the back skin of rats. After 14 days, the CPP score was recorded. Naloxone (1â mg/kg, intraperitoneally) was used to induce withdrawal on day 15, and symptoms were scored. Elevated plus maze and open field tests were performed for anxiety-related symptoms. Striata were analyzed for neurochemical changes reflected in dopamine, 3,4-dihydroxyphenyl acetic acid, gamma-aminobutyric acid, and serotonin levels. Brain oxidative changes including glutathione and lipid peroxides were assessed. The tramadol implants (T350 and T650) reduced heroin CPP and limited naloxone-induced withdrawal symptoms. The striata showed increased levels of 3,4-dihydroxyphenyl acetic acid, and serotonin and decreased levels of gamma-aminobutyric acid and dopamine after heroin withdrawal induction, which were reversed after implanting T350 and T650. Implants restore the brain oxidative state. Nonsignificant low naloxone-induced withdrawal score after the implant was used in naive subjects indicating low abuse potential of the implants. The presented tramadol implants were effective at diminishing heroin CPP and withdrawal in rats, suggesting further investigations for application in the management of opioid withdrawal.
Asunto(s)
Heroína , Naloxona , Poliésteres , Ratas Wistar , Síndrome de Abstinencia a Sustancias , Tramadol , Animales , Tramadol/farmacología , Síndrome de Abstinencia a Sustancias/tratamiento farmacológico , Masculino , Heroína/farmacología , Heroína/administración & dosificación , Ratas , Poliésteres/farmacología , Naloxona/farmacología , Implantes de Medicamentos , Dependencia de Heroína/tratamiento farmacológico , Relación Dosis-Respuesta a Droga , Analgésicos Opioides/farmacología , Analgésicos Opioides/administración & dosificación , Antagonistas de Narcóticos/farmacologíaRESUMEN
There is a significant co-occurrence of opioid use disorder (OUD) and post-traumatic stress disorder (PTSD) in clinical populations. However, the neurobiological mechanisms linking chronic opioid use, withdrawal, and the development of PTSD are poorly understood. Our previous research has shown that proinflammatory cytokines, expressed primarily by astrocytes in the dorsal hippocampus (DH), play a role in the development of heroin withdrawal-enhanced fear learning (HW-EFL), an animal model of PTSD-OUD comorbidity. Given the role of astrocytes in memory, fear learning, and opioid use, our experiments aimed to investigate their involvement in HW-EFL. Experiment 1 examined the effect of withdrawal from chronic heroin administration on GFAP surface area and volume, and identified increased surface area and volume of GFAP immunoreactivity in the dentate gyrus (DG) following 24-hour heroin withdrawal. Experiment 2 examined astrocyte morphology and synaptic interactions at the 24-hour withdrawal timepoint using an astroglial membrane-bound GFP (AAV5-GfaABC1D-lck-GFP). Although we did not detect significant changes in surface area and volume of GfaABC1D-Lck-GFP labelled astrocytes, we did observe a significant increase in the colocalization of astrocyte membranes with PSD-95 (postsynaptic density protein 95) in the DG. Experiment 3 tested if stimulating astroglial Gi signaling in the DH alters HW-EFL, and our results demonstrate this manipulation attenuates HW-EFL. Collectively, these findings contribute to our current understanding of the effects of heroin withdrawal on astrocytes and support the involvement of astrocytes in the comorbid relationship between opioid use and anxiety disorders.
Asunto(s)
Astrocitos , Miedo , Heroína , Hipocampo , Síndrome de Abstinencia a Sustancias , Astrocitos/metabolismo , Síndrome de Abstinencia a Sustancias/metabolismo , Animales , Heroína/administración & dosificación , Masculino , Hipocampo/metabolismo , Miedo/fisiología , Trastornos por Estrés Postraumático/metabolismo , Aprendizaje/fisiología , Modelos Animales de Enfermedad , Dependencia de Heroína/metabolismo , Proteína Ácida Fibrilar de la Glía/metabolismo , RatonesRESUMEN
BACKGROUND: Amidst an increasingly toxic drug supply in North America, people who inject drugs may be transitioning to smoking them. We aimed to assess changes in injecting and smoking opioids and methamphetamine among a cohort of people who inject drugs from San Diego, California. METHODS: Over five six-month periods spanning October 2020-April 2023, we assessed prevalence of injecting and smoking opioids or methamphetamine and whether participants used these drugs more frequently by smoking than injecting. Multivariable Poisson regression via generalized estimating equations was used to examine time trends. RESULTS: Of 362 participants, median age was 40 years; a minority were female (29%), Hispanic/Latinx/Mexican (45%), and housed (33%). Among this cohort, of whom 100% injected (and 84% injected and smoked) in period one (October 2020-April 2021), by period five (November 2022-April 2023), 34% only smoked, 59% injected and smoked, and 7% only injected. By period five, the adjusted relative risk (aRR) of injecting opioids was 0.41 (95% Confidence Interval [CI]: 0.33, 0.51) and the aRR for injecting methamphetamine was 0.50 (95% CI: 0.39, 0.63) compared to period one. Risks for smoking fentanyl rose significantly during period three (aRR=1.44, 95% CI: 1.06, 1.94), four (aRR=1.65, 95% CI: 1.24, 2.20) and five (aRR=1.90, 95% CI: 1.43, 2.53) compared to period one. Risks for smoking heroin and methamphetamine more frequently than injecting these drugs increased across all periods. CONCLUSIONS: Opioid and methamphetamine injection declined precipitously, with notable increases in smoking these drugs. Research is needed to understand the health consequences of these trends.
Asunto(s)
Fentanilo , Heroína , Metanfetamina , Abuso de Sustancias por Vía Intravenosa , Humanos , Femenino , Masculino , Metanfetamina/administración & dosificación , Adulto , California/epidemiología , Abuso de Sustancias por Vía Intravenosa/epidemiología , Persona de Mediana Edad , Heroína/administración & dosificación , Fumar/epidemiología , Fumar/tendencias , Estudios de Cohortes , Prevalencia , Trastornos Relacionados con Anfetaminas/epidemiologíaRESUMEN
BACKGROUND: The UK is experiencing its highest rate of drug related deaths in 25 years. Poor and inconsistent access to healthcare negatively impacts health outcomes for people who use drugs. Innovation in models of care which promote access and availability of physical treatment is fundamental. Heroin Assisted Treatment (HAT) is a treatment modality targeted at the most marginalised people who use drugs, at high risk of mortality and morbidity. The first service-provider initiated HAT service in the UK ran between October 2019 and November 2022 in Middlesbrough, England. The service was co-located within a specialist primary care facility offering acute healthcare treatment alongside injectable diamorphine. METHODS: Analysis of anonymised health records for healthcare costs (not including drug treatment) took place using descriptive statistics prior and during engagement with HAT, at both three (n=15) and six (n=12) months. Primary outcome measures were incidents of wound care, skin and soft tissue infections (SSTIs), overdose (OD) events, unplanned overnight stays in hospital, treatment engagement (general and within hospital care settings) and ambulance incidents. Secondary outcome measures were costs associated with these events. RESULTS: A shift in healthcare access for participants during HAT engagement was observed. HAT service attendance appeared to support health promoting preventative care, and reduce reactive reliance on emergency healthcare systems. At three and six months, engagement for preventative wound care and treatment for SSTIs increased at the practice. Unplanned emergency healthcare interactions for ODs, overnight hospital stays, serious SSTIs, and ambulance incidents reduced, and there was an increase in treatment engagement (i.e. a reduction in appointments which were not engaged with). There was a decrease in treatment engagement in hospital settings. Changes in healthcare utilisation during HAT translated to a reduction in healthcare costs of 58% within six months compared to the same timeframe from the period directly prior to commencing HAT. CONCLUSION: This exploratory study highlights the potential for innovative harm reduction interventions such as HAT, co-located with primary care services, to improve healthcare access and engagement for a high-risk population. Increased uptake of primary healthcare services translated to reductions in emergency healthcare use and associated costs. Although costs of HAT provision are substantial, the notable cost-savings in health care should be an important consideration in service implementation planning.
Asunto(s)
Costos de la Atención en Salud , Accesibilidad a los Servicios de Salud , Dependencia de Heroína , Atención Primaria de Salud , Humanos , Atención Primaria de Salud/economía , Dependencia de Heroína/economía , Dependencia de Heroína/terapia , Costos de la Atención en Salud/estadística & datos numéricos , Femenino , Masculino , Adulto , Reino Unido , Heroína/economía , Heroína/administración & dosificación , Sobredosis de Droga/prevención & control , Persona de Mediana Edad , Atención a la Salud/economía , Inglaterra , Tratamiento de Sustitución de Opiáceos/economíaRESUMEN
A growing body of research indicates that ß-caryophyllene (BCP), a constituent present in a large number of plants, possesses significant therapeutic properties against CNS disorders, including alcohol and psychostimulant use disorders. However, it is unknown whether BCP has similar therapeutic potential for opioid use disorders. In this study, we found that systemic administration of BCP dose-dependently reduced heroin self-administration in rats under an FR2 schedule of reinforcement and partially blocked heroin-enhanced brain stimulation reward in DAT-cre mice, maintained by optical stimulation of midbrain dopamine neurons at high frequencies. Acute administration of BCP failed to block heroin conditioned place preference (CPP) in male mice, but attenuated heroin-induced CPP in females. Furthermore, repeated dosing with BCP for 5 days facilitated the extinction of CPP in female but not male mice. In the hot plate assay, pretreatment with the same doses of BCP failed to enhance or prolong opioid antinociception. Lastly, in a substitution test, BCP replacement for heroin failed to maintain intravenous BCP self-administration, suggesting that BCP itself has no reinforcing properties. These findings suggest that BCP may have certain therapeutic effects against opioid use disorders with fewer unwanted side-effects by itself.
Asunto(s)
Heroína , Sesquiterpenos Policíclicos , Autoadministración , Animales , Masculino , Heroína/administración & dosificación , Sesquiterpenos Policíclicos/farmacología , Sesquiterpenos Policíclicos/administración & dosificación , Femenino , Ratones , Ratas , Analgésicos Opioides/farmacología , Analgésicos Opioides/administración & dosificación , Sesquiterpenos/farmacología , Sesquiterpenos/administración & dosificación , Ratas Sprague-Dawley , Relación Dosis-Respuesta a Droga , Condicionamiento Operante/efectos de los fármacos , Extinción Psicológica/efectos de los fármacos , Refuerzo en Psicología , Recompensa , Ratones Transgénicos , Nocicepción/efectos de los fármacos , Ratones Endogámicos C57BLRESUMEN
Maintenance therapy with buprenorphine and methadone is the gold standard pharmacological treatment for opioid use disorder (OUD). Despite these compounds demonstrating substantial efficacy, a significant number of patients do not show optimal therapeutic responses. The abuse liability of these medications is also a concern. Here we used rats to explore the therapeutic potential of the new long-acting pan-opioid agonist Cebranopadol in OUD. We tested the effect of cebranopadol on heroin self-administration and yohimbine-induced reinstatement of heroin seeking. In addition, we evaluated the abuse liability potential of cebranopadol in comparison to that of heroin under fixed ratio 1 (FR1) and progressive ratio (PR) operant self-administration contingencies. Oral administration of cebranopadol (0, 25, 50 µg/kg) significantly attenuated drug self-administration independent of heroin dose (1, 7, 20, 60µg/inf). Cebranopadol also reduced the break point for heroin (20 µg/inf). Finally, pretreatment with cebranopadol significantly attenuated yohimbine-induced reinstatement of drug seeking. In abuse liability experiments under FR1 contingency, rats maintained responding for heroin (1, 7, 20, 60µg/inf) to a larger extent than cebranopadol (0.03, 0.1, 0.3, 1.0, 6.0µg/inf). Under PR contingency, heroin maintained responding at high levels at all except the lowest dose, while the break point (BP) for cebranopadol did not differ from that of saline. Together, these data indicate that cebranopadol is highly efficacious in attenuating opioid self-administration and stress-induced reinstatement, while having limited abuse liability properties. Overall, the data suggest clinical potential of this compound for OUD treatment.
Asunto(s)
Heroína , Trastornos Relacionados con Opioides , Autoadministración , Yohimbina , Animales , Masculino , Trastornos Relacionados con Opioides/tratamiento farmacológico , Ratas , Heroína/administración & dosificación , Yohimbina/farmacología , Ratas Sprague-Dawley , Compuestos de Espiro/farmacología , Compuestos de Espiro/administración & dosificación , Compuestos de Espiro/uso terapéutico , Comportamiento de Búsqueda de Drogas/efectos de los fármacos , Analgésicos Opioides/farmacología , Analgésicos Opioides/administración & dosificación , Condicionamiento Operante/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Indoles/farmacología , Indoles/administración & dosificaciónRESUMEN
INTRODUCTION: The opioid crisis continues to evolve with increasing opioid-related overdose deaths among under-represented minorities. A better understanding of substance use differences in the route of administration for people using heroin and other opioids can lead to targeted strategies and interventions. METHODS: Using the 2015-2019 Treatment Episode Data Set - Admissions (TEDS-A), a multinomial logistic regression model examined the relationship between race/ethnicity and secondary substance use with route of administration in a subset of 591,078 admissions. RESULTS: For individuals reporting heroin as their primary substance, minoritized clients were both more likely to smoke (NH Blacks RR: 2.28, 95 % CI 2.16-2.41; Hispanic RR: 1.80, 95 % CI: 1.74, 1.87; Other RR: 2.09, 95 % CI: 2.00, 2.20) or inhale heroin (Hispanic RR: 1.82, 95 % CI 1.78-1.85; Other RR: 1.30, 95 % CI 1.25, 1.34) compared to non-Hispanic (NH) Whites. NH Black clients were nearly seven and a half times more likely to report inhaling (RR: 7.45, 95 % CI 7.28, 7.62) heroin over injecting it. Clients were more likely to smoke heroin compared to injection if they reported secondary drug use of methamphetamines (RR: 2.28, 95 % CI 2.21, 2.35) and other opioids (RR: 1.21, 95 % CI 1.15, 1.28). For clients reporting other opioids as their primary substance, Hispanic (RR: 1.33, 95 % CI 1.19, 1.47) and other racial/ethnic minority clients (RR: 2.50, 95 % CI 2.23, 2.79) were more likely to smoke opioids vs take it orally compared to their NH White counterparts. Individuals who reported methamphetamine use as a secondary substance were significantly more than three times as likely to smoke (RR: 3.07, 95 % CI 2.74, 3.45) or inject (RR: 3.36, 95 % CI 3.17, 3.57) compared to orally ingesting opioids, while those who reported cocaine or crack cocaine use were more than twice as likely to inject (RR: 2.22, 95 % CI 2.09-2.36) opioids than taking them orally. CONCLUSION: Findings demonstrate significant racial and ethnic differences in the route of administration. This work expands on the understanding of the complex nature of polysubstance use in the evolving opioid crisis and the secondary substance use of clients on routes of administration of opioids and heroin, highlighting the need for tailored interventions to address the treatment needs of under-represented minorities.
Asunto(s)
Analgésicos Opioides , Trastornos Relacionados con Opioides , Adolescente , Adulto , Femenino , Humanos , Masculino , Persona de Mediana Edad , Adulto Joven , Analgésicos Opioides/administración & dosificación , Analgésicos Opioides/uso terapéutico , Negro o Afroamericano/estadística & datos numéricos , Vías de Administración de Medicamentos , Etnicidad/estadística & datos numéricos , Heroína/administración & dosificación , Hispánicos o Latinos/estadística & datos numéricos , Trastornos Relacionados con Opioides/epidemiología , Trastornos Relacionados con Opioides/etnología , Estados Unidos/epidemiología , Población Blanca/estadística & datos numéricosRESUMEN
Opioid use disorder is a major public health crisis that is manifested by persistent drug-seeking behavior and high relapse frequency. Most of the available treatments rely on targeting opioid receptors using small molecules that do not provide sustained symptom alleviation. Psychoplastogens are a novel class of non-opioid drugs that produce rapid and sustained effects on neuronal plasticity, intended to produce therapeutic benefits. Ibogalogs are synthetic derivatives of iboga alkaloids that lack hallucinogenic or adverse side effects. In the current study, we examine the therapeutic potential of DM506, a novel ibogalog lacking any cardiotoxic or hallucinogenic effects, in cue-induced seeking behavior following heroin self-administration. At a single systemic dose of 40 mg/kg, DM506 significantly decreased cue-induced seeking in both male and female rats at abstinence day 1 (AD1) following heroin self-administration. Upon re-testing for cue-induced seeking at AD14, we found that males receiving DM506 continued to show decreased cue-induced seeking, an effect not observed in females. Since there is evidence of psychedelics influencing tonic GABA currents, and opioid and psychoplastogen-mediated neuroadaptations in the medial prefrontal cortex (PrL) underlying its functional effects, we performed patch-clamp recordings on PrL slices of drug-naïve rats with an acute application or chronic incubation with DM506. Tonic GABA current was decreased in slices incubated with DM506 for 2 h. qPCR analysis did not reveal any differences in the mRNA levels of GABAA receptor α and δ subunits at AD14 in heroin and saline self-administered animals that received vehicle or DM506 at AD1. Overall, our data indicate that DM506 attenuates cue-induced heroin seeking and inhibits tonic GABA current in the prelimbic cortex.
Asunto(s)
Señales (Psicología) , Comportamiento de Búsqueda de Drogas , Heroína , Ratas Sprague-Dawley , Ácido gamma-Aminobutírico , Animales , Masculino , Heroína/farmacología , Heroína/administración & dosificación , Ratas , Comportamiento de Búsqueda de Drogas/efectos de los fármacos , Femenino , Ácido gamma-Aminobutírico/metabolismo , Corteza Prefrontal/efectos de los fármacos , Corteza Prefrontal/metabolismo , Autoadministración , Dependencia de Heroína/tratamiento farmacológico , Dependencia de Heroína/metabolismo , Dependencia de Heroína/psicologíaRESUMEN
Evidence indicates that the anterior (aIC), but not posterior (pIC), insular cortex promotes cued reinstatement of cocaine seeking after extinction in rats. It is unknown whether these subregions also regulate heroin seeking and whether such involvement depends on prior extinction learning. To address these questions, we used baclofen and muscimol (BM) to inactivate the aIC or pIC bilaterally during a seeking test after extinction or prolonged withdrawal from heroin. Male Sprague-Dawley rats in the extinction groups underwent 10+ days of heroin self-administration, followed by 6+ days of extinction sessions, and subsequent cued or heroin-primed reinstatement. Results indicate that aIC inactivation increased cued reinstatement of heroin seeking after extinction, whereas pIC inactivation prevented cued reinstatement. To determine whether these effects were extinction-dependent, we conducted a subsequent study using both sexes with prolonged withdrawal. Male and female rats in the withdrawal groups underwent 10+ days of heroin self-administration, followed by cued seeking tests after 1 and 14 days of homecage withdrawal to measure incubation of heroin craving. In this case, the findings indicate that aIC inactivation had no effect on incubation of heroin craving after withdrawal in either sex, whereas pIC inactivation decreased heroin craving only in males. These findings suggest that the aIC and pIC have opposing roles in suppressing vs promoting cued heroin seeking after extinction and that these roles are distinct from those in cocaine seeking. Moreover, the incubation of craving results suggest that new contingency learning is necessary to recruit the aIC in cued heroin seeking.
Asunto(s)
Baclofeno , Señales (Psicología) , Comportamiento de Búsqueda de Drogas , Extinción Psicológica , Heroína , Corteza Insular , Muscimol , Ratas Sprague-Dawley , Autoadministración , Síndrome de Abstinencia a Sustancias , Animales , Masculino , Extinción Psicológica/efectos de los fármacos , Heroína/administración & dosificación , Heroína/farmacología , Ratas , Comportamiento de Búsqueda de Drogas/efectos de los fármacos , Comportamiento de Búsqueda de Drogas/fisiología , Baclofeno/farmacología , Baclofeno/administración & dosificación , Femenino , Corteza Insular/efectos de los fármacos , Muscimol/farmacología , Muscimol/administración & dosificación , Narcóticos/farmacología , Narcóticos/administración & dosificaciónAsunto(s)
Humanos , Masculino , Femenino , Adulto Joven , Adulto , Heroína/administración & dosificación , Heroína/análisis , Dependencia de Heroína/epidemiología , Dependencia de Heroína/prevención & control , Epidemias/economía , Epidemias/prevención & control , Epidemias/estadística & datos numéricos , España/epidemiología , Grupos de Riesgo , Apoyo SocialRESUMEN
Desde que en 1999 nos preguntábamos si la prescripción de heroína era una alternativa de tratamiento para los adictos a ella hasta hoy, en que ya hemos terminado el Proyecto Experimental de Prescripción de Estupefacientes en Andalucía (PEPSA), hemos andado un largo camino. Después del trabajo realizado en Suiza, Países Bajos y Andalucía, y los que se están haciendo en Alemania, Canadá, Cataluña y Reino Unido, se puede afirmar que la heroína es un medicamento seguro y prescribible a drogodependientes para los que otros tratamientos actualmente disponibles no han sido efectivos. La experiencia vivida durante 9 meses por los participantes de este ensayo clínico ha sido un proceso en que se ha pasado del "miedo", la "incertidumbre" y la "duda" a las situaciones estables en las que hoy aquellos pacientes viven. Sentirse "respetados y comprendidos", llenos de "esperanza y futuro" y que pueden acceder a un medicamento que les ha devuelto "la dignidad", dan la respuesta a la pregunta inicial: la heroína es una alternativa para su tratamiento
Since 1999 when we asked ourselves if the heroin prescription were an alternative of treatment for heroin addicted people until today when we already have finished the Experimental Drug Prescription Program in Andalusia (PEPSA), we have walked a long way. After the works made in Switzerland, Holland and Andalusia, and the others running or starting in Germany, Canada, Catalonia, and United Kingdom, it can be affirmed that the prescribed heroin is a safe and feasible medicine to drug dependents patients for whom other available treatments were not effectives. The experience lived during nine months by the participants of this clinical trial, has been a process that started from the "fear", the "uncertainty" and the "doubt" to the stable situations in which today this patients live. To feel "respected and understood", plenty of "hope and future" and being able to accede a medicine that has restored "their dignity", give the answer to the initial question: heroin is an alternative to their treatment
Asunto(s)
Humanos , Heroína/administración & dosificación , Planes y Programas de Salud , Calidad de Vida/psicología , Dependencia de Heroína/tratamiento farmacológico , Dependencia de Heroína/psicología , Evaluación de Programas y Proyectos de Salud , Estudios de Casos y Controles , EspañaRESUMEN
OBJETIVOS: Se evalúa el tratamiento con olanzapina de 27 pacientes en programa de metadona con consumos reiterados de cocaína sin sintomatología psicótica. PACIENTES Y MÉTODO: Los pacientes son seleccionados entre aquellos que reiteradamente presentan análisis de orina positivos a cocaína durante un período de 6 meses. Los pacientes que aceptan ser incluidos en el estudio recibieron 10 mg/24 h de olanzapina durante los 6 meses siguientes. RESULTADOS: Se produjo una disminución muy significativa de los resultados de los análisis de orina positivos tanto a cocaína como a heroína (cocaína, el 36,73 frente al 2,38 por ciento; heroína, el 16,60 frente al 4,35 por ciento); asimismo, se registró una disminución de la dosis media de metadona entre los 6 meses previos y los seis durante los que se administró olanzapina. De los 27 pacientes, cinco abandonaron el estudio. DISCUSIÓN: Parece ser que la olanzapina puede favorecer el cumplimiento del programa de metadona, ya que disminuye de forma importante el consumo de cocaína y/o heroína, y permite una reducción de la dosis diaria de metadona (AU)